<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37138875</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Combination of anti-C1qA08 and anti-mCRP a.a.35-47 antibodies is associated with renal prognosis of patients with lupus nephritis.</ArticleTitle><Pagination><StartPage>1181561</StartPage><MedlinePgn>1181561</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1181561</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1181561</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The aim of this study is to explore the prevalence and clinicopathological associations between anti-C1qA08 antibodies and anti-monomeric CRP (mCRP) a.a.35-47 antibodies and to explore the interaction between C1q and mCRP.</AbstractText><AbstractText Label="METHODS">Ninety patients with biopsy-proven lupus nephritis were included from a Chinese cohort. Plasma samples collected on the day of renal biopsy were tested for anti-C1qA08 antibodies and anti-mCRP a.a.35-47 antibodies. The associations between these two autoantibodies and clinicopathologic features and long-term prognosis were analyzed. The interaction between C1q and mCRP was further investigated by ELISA, and the key linear epitopes of the combination of cholesterol binding sequence (CBS; a.a.35-47) and C1qA08 were tested by competitive inhibition assays. The surface plasmon resonance (SPR) was used to further verify the results.</AbstractText><AbstractText Label="RESULTS">The prevalence of anti-C1qA08 antibodies and anti-mCRP a.a.35-47 antibodies were 50/90 (61.1%) and 45/90 (50.0%), respectively. Levels of anti-C1qA08 antibodies and anti-mCRP a.a.35-47 antibodies were negatively correlated with serum C3 concentrations ((0.5(0.22-1.19) g/L vs. 0.39(0.15-1.38) g/L, <i>P</i>=0.002) and (0.48(0.44-0.88) g/L vs. 0.41(0.15-1.38) g/L, <i>P</i>=0.028), respectively. Levels of anti-C1qA08 antibodies were correlated with the score of fibrous crescents and tubular atrophy (r=-0.256, <i>P</i>=0.014 and r=-0.25, <i>P</i>=0.016, respectively). The patients with double positive antibodies showed worse renal prognosis than that of the double negative group (HR 0.899 (95% CI: 0.739-1.059), <i>P</i>=0.0336). The binding of mCRP to C1q was confirmed by ELISA. The key linear epitopes of the combination were a.a.35-47 and C1qA08, which were confirmed by competitive inhibition experiments and SPR.</AbstractText><AbstractText Label="CONCLUSION">The combination of anti-C1qA08 and anti-mCRP a.a.35-47 autoantibodies could predict a poor renal outcome. The key linear epitopes of the combination of C1q and mCRP were C1qA08 and a.a.35-47. A08 was an important epitope for the classical pathway complement activation and a.a.35-47 could inhibit this process.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Liu, Tan, Yu, Ji and Zhao.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiao-Ling</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Ministry of Education (MOE) Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chronic Kidney Disease (CKD) Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chronic Kidney Disease (CKD) Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Peking University International Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Shang-Rong</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Ministry of Education (MOE) Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ming-Hui</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chronic Kidney Disease (CKD) Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="Y">Kidney Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anti-C1qA08 autoantibody</Keyword><Keyword MajorTopicYN="N">anti-mCRP a.a.35-47 autoantibody</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">renal prognosis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>4</Day><Hour>2</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37138875</ArticleId><ArticleId IdType="pmc">PMC10150958</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1181561</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (2003) 82(5):299&#x2013;308. doi: 10.1097/01.md.0000091181.93122.55</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000091181.93122.55</ArticleId><ArticleId IdType="pubmed">14530779</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaak T, Smeenk R. Clinical significance of antibodies to double stranded DNA (dsDNA) for systemic lupus erythematosus (SLE). Clin Rheumatol (1987) 6 Suppl 1:56&#x2013;73. doi: 10.1007/BF02200721</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02200721</ArticleId><ArticleId IdType="pubmed">3304800</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura M, Kanayama Y, Amastu K, Negoro N, Kohda S, Takeda T, et al. . Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis (1993) 52(1):14&#x2013;20. doi: 10.1136/ard.52.1.14</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.52.1.14</ArticleId><ArticleId IdType="pmc">PMC1004949</ArticleId><ArticleId IdType="pubmed">8427508</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T, et al. . Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum (2005) 52(4):1129&#x2013;37. doi: 10.1002/art.20980</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20980</ArticleId><ArticleId IdType="pubmed">15818711</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinico RA, Radice A, Ikehata M, Giammarresi G, Corace C, Arrigo G, et al. . Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann N Y Acad Sci (2005) 1050:193&#x2013;200. doi: 10.1196/annals.1313.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1313.020</ArticleId><ArticleId IdType="pubmed">16014534</ArticleId></ArticleIdList></Reference><Reference><Citation>Marto N, Bertolaccini ML, Calabuig E, Hughes GR, and Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis (2005) 64(3):444&#x2013;8. doi: 10.1136/ard.2004.024943</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.024943</ArticleId><ArticleId IdType="pmc">PMC1755385</ArticleId><ArticleId IdType="pubmed">15286009</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang QY, Yu F, Tan Y, Xu LX, Wu LH, Liu G, et al. . Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrol Dial Transplant (2009) 24(1):172&#x2013;8. doi: 10.1093/ndt/gfn453</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfn453</ArticleId><ArticleId IdType="pubmed">18697800</ArticleId></ArticleIdList></Reference><Reference><Citation>Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Fremeaux-Bacchi V, et al. . High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant (2006) 21(11):3115&#x2013;21. doi: 10.1093/ndt/gfl436</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfl436</ArticleId><ArticleId IdType="pubmed">16877491</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y, Yu F, Yang H, Chen M, Fang Q, Zhao MH. Autoantibodies against monomeric c-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum Immunol (2008) 69(12):840&#x2013;4. doi: 10.1016/j.humimm.2008.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2008.09.006</ArticleId><ArticleId IdType="pubmed">18852001</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjowall C, Zickert A, Skogh T, Wettero J, Gunnarsson I. Serum levels of autoantibodies against c-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther (2009) 11(6):R188. doi: 10.1186/ar2880</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2880</ArticleId><ArticleId IdType="pmc">PMC3003497</ArticleId><ArticleId IdType="pubmed">20003354</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak A, Pednekar L, Reid KB, Kishore U. Complement and non-complement activating functions of C1q: a prototypical innate immune molecule. Innate Immun (2012) 18(2):350&#x2013;63. doi: 10.1177/1753425910396252</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753425910396252</ArticleId><ArticleId IdType="pubmed">21450789</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol (2003) 24(3):148&#x2013;54. doi: 10.1016/S1471-4906(03)00030-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1471-4906(03)00030-9</ArticleId><ArticleId IdType="pubmed">12615211</ArticleId></ArticleIdList></Reference><Reference><Citation>Brencicova E, Diebold SS. Nucleic acids and endosomal pattern recognition: how to tell friend from foe? Front Cell Infect Microbiol (2013) 3:37. doi: 10.3389/fcimb.2013.00037</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2013.00037</ArticleId><ArticleId IdType="pmc">PMC3726833</ArticleId><ArticleId IdType="pubmed">23908972</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumaker VN, Hanson DC, Kilchherr E, Phillips ML, Poon PH. A molecular mechanism for the activation of the first component of complement by immune complexes. Mol Immunol (1986) 23(5):557&#x2013;65. doi: 10.1016/0161-5890(86)90119-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0161-5890(86)90119-7</ArticleId><ArticleId IdType="pubmed">3018553</ArticleId></ArticleIdList></Reference><Reference><Citation>Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol (1997) 158(10):4525&#x2013;8. doi: 10.4049/jimmunol.158.10.4525</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.158.10.4525</ArticleId><ArticleId IdType="pubmed">9144462</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhecke D, Roumenina LT, Wan H, Osthoff M, Schaller M. Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay. Arthritis Rheum (2012) 64(11):3706&#x2013;14. doi: 10.1002/art.34605</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34605</ArticleId><ArticleId IdType="pubmed">22740328</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang Y, Tan Y, Li Y, Zhang J, Guo Y, Guo Z, et al. . Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis. Kidney Int (2016) 90(6):1357&#x2013;67. doi: 10.1016/j.kint.2016.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2016.08.010</ArticleId><ArticleId IdType="pubmed">27745701</ArticleId></ArticleIdList></Reference><Reference><Citation>James LP, Lamps LW, McCullough S, Hinson JA. Interleukin 6 and hepatocyte regeneration in acetaminophen toxicity in the mouse. Biochem Biophys Res Commun (2003) 309(4):857&#x2013;63. doi: 10.1016/j.bbrc.2003.08.085</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2003.08.085</ArticleId><ArticleId IdType="pubmed">13679052</ArticleId></ArticleIdList></Reference><Reference><Citation>Biro A, Rovo Z, Papp D, Cervenak L, Varga L, Fust G, et al. . Studies on the interactions between c-reactive protein and complement proteins. Immunology (2007) 121(1):40&#x2013;50. doi: 10.1111/j.1365-2567.2007.02535.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2007.02535.x</ArticleId><ArticleId IdType="pmc">PMC2265924</ArticleId><ArticleId IdType="pubmed">17244159</ArticleId></ArticleIdList></Reference><Reference><Citation>Potempa LA, Siegel JN, Fiedel BA, Potempa RT, Gewurz H. Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human c-reactive protein subunit. Mol Immunol (1987) 24(5):531&#x2013;41. doi: 10.1016/0161-5890(87)90028-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0161-5890(87)90028-9</ArticleId><ArticleId IdType="pubmed">2443837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, Lu W, et al. . Cell membranes and liposomes dissociate c-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J (2007) 21(1):284&#x2013;94. doi: 10.1096/fj.06-6722com</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.06-6722com</ArticleId><ArticleId IdType="pubmed">17116742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji SR, Zhang SH, Chang Y, Li HY, Wang MY, Lv JM, et al. . C-reactive protein: The most familiar stranger. J Immunol (2023) 210(6):699&#x2013;707. doi: 10.4049/jimmunol.2200831</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2200831</ArticleId><ArticleId IdType="pubmed">36881905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibraheem MR, Daniel M, Margaret EO, Jenna MBA, Mihee LC, Matthew SN, et al. . C-reactive protein in gallbladder diseases: diagnostic and therapeutic insights. Biophysics Rep (2020) 6(2-3):49&#x2013;67. doi: 10.1007/s41048-020-00108-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41048-020-00108-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker GJ, Waldburger M, Hughes GR, Pepys MB. Value of serum c-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis (1980) 39(1):50&#x2013;2. doi: 10.1136/ard.39.1.50</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.39.1.50</ArticleId><ArticleId IdType="pmc">PMC1000469</ArticleId><ArticleId IdType="pubmed">7377859</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig S, Gorevic P, Weissmann G. C-reactive protein in systemic lupus erythematosus. Arthritis Rheum (1977) 20(5):1065&#x2013;70. doi: 10.1002/art.1780200505</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780200505</ArticleId><ArticleId IdType="pubmed">869953</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesickova SS, Rysava R, Lenicek M, Vitek L, Potlukova E, Hruskova Z, et al. . Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. Arthritis Res Ther (2015) 17:371. doi: 10.1186/s13075-015-0879-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0879-8</ArticleId><ArticleId IdType="pmc">PMC4718018</ArticleId><ArticleId IdType="pubmed">26704903</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QY, Li HY, Fu G, Yu F, Wu Y, Zhao MH. Autoantibodies against c-reactive protein influence complement activation and clinical course in lupus nephritis. J Am Soc Nephrol (2017) 28(10):3044&#x2013;54. doi: 10.1681/ASN.2016070735</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016070735</ArticleId><ArticleId IdType="pmc">PMC5619952</ArticleId><ArticleId IdType="pubmed">28566480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 40(9):1725. doi: 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. a disease activity index for lupus patients. the committee on prognosis studies in SLE. Arthritis Rheum (1992) 35(6):630&#x2013;40. doi: 10.1002/art.1780350606</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780350606</ArticleId><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum (1989) 32(9):1107&#x2013;18. doi: 10.1002/anr.1780320909</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anr.1780320909</ArticleId><ArticleId IdType="pubmed">2775320</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, 3rd, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int (1994) 45(2):544&#x2013;50. doi: 10.1038/ki.1994.70</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1994.70</ArticleId><ArticleId IdType="pubmed">8164443</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int (1984) 25(4):689&#x2013;95. doi: 10.1038/ki.1984.75</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1984.75</ArticleId><ArticleId IdType="pubmed">6482173</ArticleId></ArticleIdList></Reference><Reference><Citation>Roumenina LT, Radanova M, Atanasov BP, Popov KT, Kaveri SV, Lacroix-Desmazes S, et al. . Heme interacts with c1q and inhibits the classical complement pathway. J Biol Chem (2011) 286(18):16459&#x2013;69. doi: 10.1074/jbc.M110.206136</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.206136</ArticleId><ArticleId IdType="pmc">PMC3091251</ArticleId><ArticleId IdType="pubmed">21454703</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Cui Z, Yang R, Jia XY, Zhang Y, Zhao MH. Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney Int (2009) 76(10):1108&#x2013;15. doi: 10.1038/ki.2009.348</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2009.348</ArticleId><ArticleId IdType="pubmed">19741587</ArticleId></ArticleIdList></Reference><Reference><Citation>Maningding E, Dall'Era M, Trupin L, Murphy LB, Yazdany J. Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: The California lupus surveillance project. Arthritis Care Res (2020) 72(5):622&#x2013;9. doi: 10.1002/acr.23887</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23887</ArticleId><ArticleId IdType="pmc">PMC6872905</ArticleId><ArticleId IdType="pubmed">31115180</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez Cruz B, Alonso F, Calvo Alen J, Pego-Reigosa JM, Lopez-Longo FJ, Galindo-Izquierdo M, et al. . Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of hispanics: European caucasians versus Latin American mestizos (data from the RELESSER registry). Lupus (2020) 29(1):27&#x2013;36. doi: 10.1177/0961203319889667</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319889667</ArticleId><ArticleId IdType="pubmed">31801040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L, Cunningham PN, Quigg RJ. Complement in lupus nephritis: New perspectives. Kidney Dis (2015) 1(2):91&#x2013;9. doi: 10.1159/000431278</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000431278</ArticleId><ArticleId IdType="pmc">PMC4934819</ArticleId><ArticleId IdType="pubmed">27536669</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno M, Suzuki Y, Ito Y. Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology. Clin Exp Nephrol (2018) 22(1):3&#x2013;14. doi: 10.1007/s10157-017-1405-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-017-1405-x</ArticleId><ArticleId IdType="pubmed">28341889</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjowall C, Olin AI, Skogh T, Wettero J, Morgelin M, Nived O, et al. . C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. Autoimmunity (2013) 46(3):205&#x2013;14. doi: 10.3109/08916934.2013.764992</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916934.2013.764992</ArticleId><ArticleId IdType="pubmed">23331132</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>